A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Recruiting

Phase 1

Sponsor:

Amneal Pharmaceuticals, LLC

Code:

NCT06267274

Conditions

Open-angle Glaucoma

Ocular Hypertension

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bimatoprost Ophthalmic Solution, 0.01%

LUMIGAN® (bimatoprost ophthalmic solution) 0.01%

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information